Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula (unspecified eye)
ICD-10 E09.3539 is a billable code used to indicate a diagnosis of drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula (unspecified eye).
E09.3539 refers to diabetes mellitus that is induced by drugs or chemicals, leading to significant complications such as proliferative diabetic retinopathy and traction retinal detachment. Proliferative diabetic retinopathy is characterized by the growth of new blood vessels in the retina, which can lead to severe vision impairment. In this specific case, the traction retinal detachment does not involve the macula, which is crucial for central vision. The condition is often associated with poorly controlled blood glucose levels, indicated by elevated HbA1c levels, and may require insulin management or other pharmacological interventions. The underlying cause of the diabetes must be clearly documented, as it differentiates this condition from other types of diabetes mellitus. Management typically involves a multidisciplinary approach, including endocrinology for diabetes control and ophthalmology for retinal complications.
Detailed history of diabetes management, including medication history and HbA1c levels.
Patients presenting with uncontrolled diabetes due to medication side effects.
Ensure clarity on the causative agent of diabetes and its management.
Comprehensive eye examination findings, including details on retinopathy and retinal detachment.
Patients with vision changes due to diabetic retinopathy.
Document the extent of retinal detachment and its implications for vision.
Used when a patient with drug-induced diabetes presents for a comprehensive eye exam.
Document the patient's diabetes history, medications, and findings from the eye exam.
Ophthalmologists should be aware of the patient's diabetes management and any related complications.
Specifying drug-induced diabetes is crucial for accurate treatment planning and management, as it influences the choice of medications and monitoring strategies.
